Today, EPPL is one of the most well-known manufacturers of Mebendazole. Other products of EPPL include Albendazole, Diclofenac Sodium, as well as a number of other intermediates used in the manufacture of the said products.
|Product Name||End Use|
The company is committed to maintain international quality standards for its entire range of products through constant process and technology updates.
EPPL was a company with a mere 4 reactors when established, has now grown to a considerable size of 38 reactors spread across approximately 7000 square meters of land.
|Land||Approximately 7000 square meters|
|Building||4 blocks with Ground + 3 floors construction|
|Stainless Steel Reactors||26|
|Glass Line Reactors||07|
We have 4 different blocks within the premises with reactor capacities ranging from 500L to 10kL, with a combined reactor volume of 1.26 mega-liters. We also have a full-fledged pilot plant with glass line reactors, stainless steel reactors and glass assemblies, where we can carry out development of new products and chemical reaction studies before taking the products into commercial production.
A macro view of the infrastructure can be gauged by the production capacity of the plant as given below:
|Product Name||Production Capacity (MT/month)|
|Mebendazole (off white)||15|
The company has all the valid permits and licenses required for the smooth functioning of the company, such as:
• Factory Act License
• Gujarat Pollution Control Board Consent
• Explosive License
• Prohibition License
• Revised Schedule ‘M’- FDA
• API Manufacturing License
Since its inception the company has grown from pillar to post and has established quite a name for itself in the local as well global market. EPPL has exported to a number of countries such as Bangladesh, Brazil, Cyprus, Egypt, France, Germany, Italy, Kenya Mexico, Pakistan, South Korea, Sri Lanka, Vietnam, Singapore and UAE.
In the local market, we cater to well renowned companies which include a number of MNC’s.
EPPL also offers the Open part of DMF for Mebendazole and Albendazole.
Presently, EPPL manufactures Diclofenac Sodium and its intermediates for the local market. We also have a number of new API’s and intermediates which have crossed the development stage and are ready to be commercialized, a few of which are listed below :
|Sr.No.||Chemical / Intermediate Name||Common Name||CAS No.||End Use in API|
|3||5-Amino Salicylic Acid||5-ASA||89-57-6||Mesalamine or Mesalazine|
|4||5-[2-Ethoxy-5-(4-methylpiperazin-1-yl-sulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazol[4,3d]pyrimidin-7-one||Sildenafil Base||139755-83-2||Sildenafil Citrate|
|6||Tramadol Base and Intermediates||-||1109217-84-6 (Base)22204-88-2(HCl)||Opiod Analgesic|
|7||2 Chloromethyl 3,5-dimethyl 4-methoxy pyridine hydrochloride||-||86604-75-3||Omeprazole|
|8||Chlorhexidine base||-||55-56-1||Chlorhexidine Glucoate|
|10||1-(2, 6- Dichlorophenol)-2-Indolinone||INDOLENONE||15307-86-5||Diclofenac Salts|
With WHO declaring Albendazole as an essential drug for the African nations, EPPL is looking to tap the export market for the African nations. The launching of the above mentioned products in the market will boost the credibility as well as financials of the company to a considerable extent. The local market for Diclofenac Sodium is ripe as ever and for EPPL, exporting the API to non-regulated markets is next on the cards. Also, the planning for future growth includes getting a WHO certificate for the manufacturing facility and expansion in manufacturing capacities of the existing APIs.